YL-109CAS# 36341-25-0 |
- Hydroxyfasudil
Catalog No.:BCC1635
CAS No.:105628-72-6
- chroman 1
Catalog No.:BCC1480
CAS No.:1273579-40-0
- Y-27632 dihydrochloride
Catalog No.:BCC1273
CAS No.:129830-38-2
- H-1152
Catalog No.:BCC1615
CAS No.:451462-58-1
- H-1152 dihydrochloride
Catalog No.:BCC1616
CAS No.:871543-07-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 36341-25-0 | SDF | Download SDF |
PubChem ID | 5769211 | Appearance | Powder |
Formula | C14H11NO2S | M.Wt | 257.31 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 100 mg/mL (388.64 mM; Need ultrasonic) | ||
Chemical Name | (4E)-4-(3H-1,3-benzothiazol-2-ylidene)-2-methoxycyclohexa-2,5-dien-1-one | ||
SMILES | COC1=CC(=C2NC3=CC=CC=C3S2)C=CC1=O | ||
Standard InChIKey | GYDCERBFGYCQCZ-NTEUORMPSA-N | ||
Standard InChI | InChI=1S/C14H11NO2S/c1-17-12-8-9(6-7-11(12)16)14-15-10-4-2-3-5-13(10)18-14/h2-8,15H,1H3/b14-9+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
YL-109 Dilution Calculator
YL-109 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.8864 mL | 19.4318 mL | 38.8636 mL | 77.7273 mL | 97.1591 mL |
5 mM | 0.7773 mL | 3.8864 mL | 7.7727 mL | 15.5455 mL | 19.4318 mL |
10 mM | 0.3886 mL | 1.9432 mL | 3.8864 mL | 7.7727 mL | 9.7159 mL |
50 mM | 0.0777 mL | 0.3886 mL | 0.7773 mL | 1.5545 mL | 1.9432 mL |
100 mM | 0.0389 mL | 0.1943 mL | 0.3886 mL | 0.7773 mL | 0.9716 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. IC50 value: 85.7 nM(MCF-7 cells proliferation) [1] Target: AhR signaling activcator in vitro: YL-109 strongly inhibited cell proliferation of MCF-7 cells in a dose-dependent manner (IC50= 85.8 nM). Surprisingly, YL-109 had an anti-proliferative effect in a dose-dependent manner (IC50 = 4.02 μM) on MDA-MB-231 cells. YL-109 repressed the sphere-forming ability and the expression of stem cell markers in MDA-MB-231 mammosphere cultures. YL-109 increased the expression of carboxyl terminus of Hsp70-interacting protein (CHIP), which suppresses tumorigenic and metastatic potential of breast cancer cells by inhibiting the oncogenic pathway. YL-109 induced CHIP transcription because of the recruitment of the aryl hydrocarbon receptor (AhR) to upstream of CHIP gene in MDA-MB-231 cells. Consistently, the antitumor effects of YL-109 were depressed by CHIP or AhRknockdown in MDA-MB-231 cells [1]. in vivo: Mice treated with vehicle showed significantly enlarged tumors, whereas mice treated with YL-109 showed attenuated tumor growth using MCF-7 cells. Interestingly, YL-109 also suppressed tumor growth in mice injected with MDA-MB-231 cells. Compared with the vehicle control, YL-109 significantly reduced lung metastasis [1].
References:
[1]. Hiyoshi H, et al. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. Sci Rep. 2014 Nov 18;4:7095.
- Piroxicam
Catalog No.:BCC3841
CAS No.:36322-90-4
- Broussonol E
Catalog No.:BCN7996
CAS No.:363134-28-5
- Prostaglandin E2
Catalog No.:BCC7316
CAS No.:363-24-6
- Hederasaponin B
Catalog No.:BCN1085
CAS No.:36284-77-2
- Pitolisant oxalate
Catalog No.:BCC1864
CAS No.:362665-57-4
- Pitolisant
Catalog No.:BCC1862
CAS No.:362665-56-3
- Clemaphenol A
Catalog No.:BCN7834
CAS No.:362606-60-8
- (±)-SLV 319
Catalog No.:BCC7954
CAS No.:362519-49-1
- TC 1
Catalog No.:BCC7450
CAS No.:362512-81-0
- Cyclo(D-Leu-L-Pro)
Catalog No.:BCN4028
CAS No.:36238-67-2
- Jatrorrhizine
Catalog No.:BCN5319
CAS No.:3621-38-3
- Columbamine
Catalog No.:BCN2722
CAS No.:3621-36-1
- Cyclo(L-Ala-L-Pro)
Catalog No.:BCN4012
CAS No.:36357-32-1
- Oxyphyllenone A
Catalog No.:BCN7103
CAS No.:363610-34-8
- 4-Methylhistamine dihydrochloride
Catalog No.:BCC7337
CAS No.:36376-47-3
- α,α'-Bis(4-hydroxy-3,5-dimethylphenyl)-1,4-diisopropylbenzene
Catalog No.:BCC9196
CAS No.:36395-57-0
- Metoclopramide
Catalog No.:BCC1743
CAS No.:364-62-5
- Diazoxide
Catalog No.:BCC6868
CAS No.:364-98-7
- A 419259
Catalog No.:BCC4307
CAS No.:364042-47-7
- N-p-trans-Coumaroyltyramine
Catalog No.:BCN5320
CAS No.:36417-86-4
- Tolperisone HCl
Catalog No.:BCC4740
CAS No.:3644-61-9
- 6-Hydroxystigmasta-4,22-dien-3-one
Catalog No.:BCN5321
CAS No.:36450-01-8
- 6beta-Hydroxystigmast-4-en-3-one
Catalog No.:BCN5322
CAS No.:36450-02-9
- Lucidenic acid SP1
Catalog No.:BCN7969
CAS No.:364622-33-3
2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.[Pubmed:25403352]
Sci Rep. 2014 Nov 18;4:7095.
Breast cancer is the most common malignancy among women and has poor survival and high recurrence rates for aggressive metastatic disease. Notably, triple-negative breast cancer (TNBC) is a highly aggressive cancer and there is no preferred agent for TNBC therapy. In this study, we show that a novel agent, 2-(4-hydroxy-3-methoxyphenyl)-benzothiazole (YL-109), has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. In addition, YL-109 repressed the sphere-forming ability and the expression of stem cell markers in MDA-MB-231 mammosphere cultures. YL-109 increased the expression of carboxyl terminus of Hsp70-interacting protein (CHIP), which suppresses tumorigenic and metastatic potential of breast cancer cells by inhibiting the oncogenic pathway. YL-109 induced CHIP transcription because of the recruitment of the aryl hydrocarbon receptor (AhR) to upstream of CHIP gene in MDA-MB-231 cells. Consistently, the antitumor effects of YL-109 were depressed by CHIP or AhR knockdown in MDA-MB-231 cells. Taken together, our findings indicate that a novel agent YL-109 inhibits cell growth and metastatic potential by inducing CHIP expression through AhR signaling and reduces cancer stem cell properties in MDA-MB-231 cells. It suggests that YL-109 is a potential candidate for breast cancer therapy.